secwatch.observer — SEC 8-K summary
======================================

Issuer:     CV Sciences, Inc. (CVSI)
CIK:        0001510964
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0000950170-25-107984
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CV Sciences Q2 revenue $3.6M (-8% YoY); first positive adjusted EBITDA in six years
--------------------------------------------------------------------------------

- Revenue $3.6M, down 8% from $4.0M in Q2 2024; units sold down 7%, avg price down 2.8%.
- Gross margin 50.9%, highest since Q3 2019, up from 47.0% in Q2 2024.
- Adjusted EBITDA positive $0.1M, first since Q2 2019, vs -$6k in Q2 2024.
- Cash balance $0.9M at quarter end, up from $0.5M at end of 2024.
- CEO cites state regulatory pressure for sales decline; pushing M&A and new products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1510964/000095017025107984/0000950170-25-107984-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1510964/000095017025107984/cvsi-20250813.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-107984

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer